Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Polomar Health ServicesPMHS EV-to-EBITDA is -4.82 as of Jul. 25, 2026. The stock has 3 warning signs investors should review. Among 507 Healthcare Providers & Services companies, Polomar Health Services ranks worse than 197238.46% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Polomar Health Services's enterprise value is $2.98 Mil.
Polomar Health Services's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.62 Mil. Therefore, Polomar Health Services's EV-to-EBITDA for today is -4.82.
The historical rank and industry rank for Polomar Health Services's EV-to-EBITDA or its related term are showing as below:
PMHS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1174.15 Med: -25.57 Max: -0.27
Current: -4.82
During the past 7 years, the highest EV-to-EBITDA of Polomar Health Services was -0.27. The lowest was -1174.15. And the median was -25.57.
PMHS's EV-to-EBITDA is ranked worse than 100% of 507
companies
in the Healthcare Providers & Services industry
Industry Median: 10.92
vs PMHS: -4.82
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Polomar Health Services (OTCPK:PMHS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Polomar Health Services's PE Ratio (TTM) for today is calculated as:
Polomar Health Services's share price for today is $0.08.
Polomar Health Services's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.370.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Polomar Health Services's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polomar Health Services EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Polomar Health Services's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Polomar Health Services's EV-to-EBITDA falls into.
Polomar Health Services's current Enterprise Value is $2.98 Mil.
Polomar Health Services's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polomar Health Services (PMHS) has a EV-to-EBITDA of -4.82 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Polomar Health Services. According to the industry distribution chart, Polomar Health Services ranks #999999 out of 507 companies in the Healthcare Providers & Services industry.
Is Polomar Health Services' EV-to-EBITDA too high?
Polomar Health Services' current EV-to-EBITDA is -4.82. Based on the distribution chart, Polomar Health Services ranks #999999 out of 507 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Polomar Health Services' EV-to-EBITDA compare to DHTI and RDGT?
According to the Healthcare Providers & Services industry distribution chart, Polomar Health Services ranks #999999 out of 507 companies for EV-to-EBITDA. This places Polomar Health Services in the lower half of its industry. The industry median EV-to-EBITDA is 10.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.92, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Polomar Health Services. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polomar Health Services's current EV-to-EBITDA is -4.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polomar Health Services stock overvalued right now?
Based on GuruFocus' analysis, Polomar Health Services (PMHS) is currently considered Possible Value Trap. The stock's GF Value™ is $12.53, compared to a current price of $0.08 — trading 99.4% below its estimated fair value. The current EV-to-EBITDA is -4.82. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Polomar Health Services (PMHS), the current EV-to-EBITDA is -4.82 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Polomar Health Services Inc is a U.S.-based healthcare company specializing in retail compounding pharmacy services and prescription fulfillment for telehealth platforms. It is also licensed as a Special Sterile Compounding Pharmacy, permit #PH35277, which authorizes the licensed entity to dispense injectable and other sterile compounds (eye drops, infused therapeutics) upon receipt of a valid prescription. The firm is presently licensed and authorized to fulfill and deliver compounded prescribed medications in 28 states.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMHS has been successfully added to your 
